Literature DB >> 17511723

Practice patterns regarding prostate cancer and benign prostatic hyperplasia in Japanese primary care practitioners.

Takashi Fukagai1, Kunitaka Maruyama, Masakazu Nagata, Masashi Morita, Michio Naoe, Hideki Yoshida.   

Abstract

OBJECTIVE: Although primary care practitioners (PCP) take an active role in diagnosis of prostate disorders in Western countries, how PCP take part in management of prostate disease still differs worldwide by country. We investigated practice and referral patterns concerning prostate disease among Japanese PCP and compared these with reported patterns in the West.
METHODS: A 26-question multiple-choice questionnaire was mailed to 935 PCP in Tokyo for anonymous completion. Most items involved prostate cancer screening or management of benign prostatic hyperplasia (BPH).
RESULTS: The survey was completed by 281 non-urological practitioners, among whom digital rectal examination was performed by 43%. Prostate-specific antigen (PSA) was determined in serum by 89%. For asymptomatic men older than 50, serum PSA was determined routinely each year by only 17%. When PSA was 4.1-10.0 ng/mL, 70% of respondents immediately referred patients to urologists, while 18% did not make a referral unless PSA exceeded 10.0 ng/mL. Seventy-four percent prescribed medication for benign prostate hypertrophy; among these respondents, 87% reported common use of alpha-blockers. Although 31% of respondents were aware of the International Prostate Symptom Score (IPSS), only 2% used it.
CONCLUSIONS: Although Japanese PCP were involved increasingly in diagnosis and management of prostate disease, degree and proficiency of involvement were too limited and less than in Western countries. Continuing medical education appears desirable for PCP in Japan regarding prostate disease.

Entities:  

Mesh:

Year:  2007        PMID: 17511723     DOI: 10.1111/j.1442-2042.2007.01742.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  18 in total

1.  Longitudinal changes in peak urinary flow rates in a community based cohort.

Authors:  R O Roberts; S J Jacobsen; D J Jacobson; T Rhodes; C J Girman; M M Lieber
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

Review 2.  Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview.

Authors:  C G Roehrborn; G Bartsch; R Kirby; G Andriole; P Boyle; J de la Rosette; P Perrin; E Ramsey; J Nordling; G De Campos Freire; S Arap
Journal:  Urology       Date:  2001-11       Impact factor: 2.649

3.  EAU Guidelines on benign prostatic hyperplasia (BPH).

Authors:  J J de la Rosette; G Alivizatos; S Madersbacher; M Perachino; D Thomas; F Desgrandchamps; M de Wildt
Journal:  Eur Urol       Date:  2001-09       Impact factor: 20.096

4.  [Guidelines for German urologists on diagnosis of benign prostate syndrome].

Authors:  R Berges; K Dreikorn; K Höfner; U Jonas; K U Laval; S Madersbacher; M C Michel; R Muschter; M Oelke; L Pientka; C Tschuschke; U Tunn; K Schalkhäuser; B Göckel-Beining; A Heidenreich; H Rübben; K Schalkhäuser; W Thon; J Thüroff; W Weidner
Journal:  Urologe A       Date:  2003-03-12       Impact factor: 0.639

5.  [Guidelines of German urologists on therapy of benign prostate syndrome].

Authors:  R Berges; K Dreikorn; K Höfner; U Jonas; K U Laval; S Madersbacher; M C Michel; R Muschter; M Oelke; L Pientka; C Tschuschke; U Tunn; H Palmtag; M Goepel; K Schalhhäuser; B Göckeel-Beining; A Heidenreich; H Rübben; K Schalkerhäuser; W Thon; J Thüroff; W Weidner
Journal:  Urologe A       Date:  2003-03-22       Impact factor: 0.639

6.  AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations.

Authors: 
Journal:  J Urol       Date:  2003-08       Impact factor: 7.450

7.  The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion.

Authors:  J Curtis Nickel; Fred Saad
Journal:  Can J Urol       Date:  2004-04       Impact factor: 1.344

8.  Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

Authors:  C G Roehrborn; J McConnell; J Bonilla; S Rosenblatt; P B Hudson; G H Malek; P F Schellhammer; R Bruskewitz; A M Matsumoto; L H Harrison; H A Fuselier; P Walsh; J Roy; G Andriole; M Resnick; J Waldstreicher
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

9.  EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines).

Authors:  Stephan Madersbacher; Gerasimos Alivizatos; Jorgen Nordling; Carlos Rioja Sanz; Mark Emberton; Jean J M C H de la Rosette
Journal:  Eur Urol       Date:  2004-11       Impact factor: 20.096

Review 10.  A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same?

Authors:  J Irani; C T Brown; J van der Meulen; M Emberton
Journal:  BJU Int       Date:  2003-12       Impact factor: 5.588

View more
  3 in total

1.  [Rates of prostate-specific antigen testing for early detection of prostate cancer: a first comparison of German results with current international data].

Authors:  S Lebentrau; M May; O Maurer; M Schostak; M Lehsnau; T Ecke; S Al-Dumaini; S Hallmann; A M Ahmed; V Braun; A Haferkamp; R M Bauer; C G Stief; D Baumunk; B Hoschke; H-P Braun; C Schäfer; M Hipp; J Maurer; K-P Braun; I Wolff; S Brookman-May; C Gilfrich
Journal:  Urologe A       Date:  2014-05       Impact factor: 0.639

Review 2.  Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines: a systematic review.

Authors:  Saskia Van der Meer; Sabine A M Löwik; Willem H Hirdes; Rien M Nijman; Klaas Van der Meer; Josette E H M Hoekstra-Weebers; Marco H Blanker
Journal:  BMC Fam Pract       Date:  2012-10-11       Impact factor: 2.497

3.  Chinese urologists' views of practice patterns in the diagnosis and treatment of benign prostatic hyperplasia: a nationwide survey.

Authors:  Nan Wu; Jian Sun; Pulin Yu; Zhenqiu Sun
Journal:  Int Neurourol J       Date:  2012-12-31       Impact factor: 2.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.